APA (7th ed.) Citation

Mok, T. S., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., . . . Wu, Y. (2021). Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. Drugs, 81(2), 257. https://doi.org/10.1007/s40265-020-01441-6

Chicago Style (17th ed.) Citation

Mok, Tony S., et al. "Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations." Drugs 81, no. 2 (2021): 257. https://doi.org/10.1007/s40265-020-01441-6.

MLA (9th ed.) Citation

Mok, Tony S., et al. "Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations." Drugs, vol. 81, no. 2, 2021, p. 257, https://doi.org/10.1007/s40265-020-01441-6.